Kallyope Overview

  • Founded

  • 2015

Founded
  • Status

  • Private

  • Employees

  • 101

Employees
  • Latest Deal Type

  • Series D

  • Latest Deal Amount

  • $236M

  • Investors

  • 19

Kallyope General Information

Description

Operator of a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company's cross-disciplinary team integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics thereby, providing users with an understanding of gut-brain biology that leads to transformational therapeutics for the improvement of human health.

Contact Information

Website
www.kallyope.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 430 East 29th Street
  • 10th Floor
  • New York, NY 10016
  • United States
+1 (646) 000-0000

Kallyope Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kallyope Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series D) 27-Jan-2022 $236M 00000 00.000 Completed Generating Revenue
3. Later Stage VC (Series C) 25-Mar-2020 00000 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 05-Dec-2018 $87M $131M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 10-Dec-2015 $44M $44M 0000 Completed Generating Revenue
To view Kallyope’s complete valuation and funding history, request access »

Kallyope Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00 00 00 00 00.000
Series B 43,454,779 $0.001000 8% $2 $2 1x $2 20.85%
Series A 44,050,000 $0.001000 8% $1 $1 1x $1 21.13%
To view Kallyope’s complete cap table history, request access »

Kallyope Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company'
Biotechnology
New York, NY
101 As of 2023
00000
0.000 0000-00-00
00000000000 00000

000000

it in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sin
0000 000000000
Brisbane, CA
00 As of 0000
000.00
00000000000 000.00

000000

m ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000 000000000
Cambridge, MA
0000 As of 0000
00000
0.000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kallyope Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Second Genome Venture Capital-Backed Brisbane, CA 00 000.00 00000000000 000.00
000000 Venture Capital-Backed Cambridge, MA 0000 00000 00000000000 00000
0000 Formerly VC-backed San Mateo, CA 00 000.00 000000&0 000.00
000000000000 Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
000000000 00000000 Venture Capital-Backed Dublin, OH 0 000.00 0000 000.00
You’re viewing 5 of 42 competitors. Get the full list »

Kallyope Patents

  • 33

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 5

    Pending

  • 000

    Expiring in next 12 mo

Kallyope Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021297323-A1 Ampk activators Pending 26-Jun-2020 00000000
CA-3183575-A1 Ampk activators Pending 26-Jun-2020 00000000
US-11407768-B2 Ampk activators Active 26-Jun-2020 00000000 000
US-20220002317-A1 Ampk activators Active 26-Jun-2020 00000000
US-20220340599-A1 Ampk activators Pending 26-Jun-2020 A61P1/00
To view Kallyope’s complete patent history, request access »

Kallyope Executive Team (16)

Name Title Board Seat Contact Info
James Galeota Jr. Chief Executive Officer, President & Board Member
Nancy Thornberry Chairman, Research & Development & Founding CEO
Patrick Flanigan III Chief Financial Officer
Shirly Pinto Ph.D Chief Scientific Officer & Senior Vice President
Robert Barretto Ph.D Senior Scientist
You’re viewing 5 of 16 executive team members. Get the full list »

Kallyope Board Members (10)

Name Representing Role Since
Amy Schulman JD Polaris Partners Board Member 000 0000
Jeffrey Goater The Column Group Board Member 000 0000
Joshua Wolfe Lux Capital Strategic Advisor & Board Member 000 0000
Nancy Thornberry Kallyope Chairman, Research & Development & Founding CEO 000 0000
Peter Hecht Ph.D Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Kallyope Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kallyope Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bill Gates Angel (individual) Minority 000 0000 000000 0
DNS Capital Venture Capital Minority 000 0000 000000 0
Hartford Healthcare Endowment Corporate Venture Capital Minority 000 0000 000000 0
Mubadala Investment Company Sovereign Wealth Fund Minority 000 0000 000000 0
Parkwood Family Office Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »

Ready to get started?

Request a free trial